DK3142666T3 - 5-HT4-receptoragonist til gastroparese - Google Patents
5-HT4-receptoragonist til gastroparese Download PDFInfo
- Publication number
- DK3142666T3 DK3142666T3 DK15793503.2T DK15793503T DK3142666T3 DK 3142666 T3 DK3142666 T3 DK 3142666T3 DK 15793503 T DK15793503 T DK 15793503T DK 3142666 T3 DK3142666 T3 DK 3142666T3
- Authority
- DK
- Denmark
- Prior art keywords
- gastroparesis
- receptor agonist
- agonist
- receptor
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 206010021518 Impaired gastric emptying Diseases 0.000 title 1
- 208000001288 gastroparesis Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994432P | 2014-05-16 | 2014-05-16 | |
| PCT/JP2015/002478 WO2015174098A1 (en) | 2014-05-16 | 2015-05-18 | 5-ht4 receptor agonist for gastroparesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3142666T3 true DK3142666T3 (da) | 2020-08-31 |
Family
ID=54479646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15793503.2T DK3142666T3 (da) | 2014-05-16 | 2015-05-18 | 5-HT4-receptoragonist til gastroparese |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9833447B2 (de) |
| EP (1) | EP3142666B1 (de) |
| JP (2) | JP6754033B2 (de) |
| KR (1) | KR102526521B1 (de) |
| CN (2) | CN106456620A (de) |
| BR (1) | BR112016024830A2 (de) |
| CA (1) | CA2948890C (de) |
| DK (1) | DK3142666T3 (de) |
| ES (1) | ES2812100T3 (de) |
| MX (1) | MX373078B (de) |
| RU (1) | RU2708686C2 (de) |
| TW (2) | TWI710372B (de) |
| WO (1) | WO2015174098A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110398541B (zh) * | 2018-04-24 | 2023-03-10 | 东莞市东阳光动物保健药品有限公司 | 一种分离和测定枸橼酸马罗匹坦及其光学异构体的方法 |
| CN116940361A (zh) * | 2020-12-29 | 2023-10-24 | 纽洛佳斯特拉斯公司 | 美托哌丙嗪及其盐的代谢方法 |
| CN116983314B (zh) * | 2023-09-28 | 2024-02-09 | 首都医科大学附属北京中医医院 | D1-like受体激动剂在制备增强胃动力药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770262B2 (en) * | 2000-03-30 | 2004-08-03 | Questcor Pharmaceuticals, Inc. | Nasal administration of agents for the treatment of gastroparesis |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| RU2374244C2 (ru) * | 2004-01-07 | 2009-11-27 | Арикс Терапьютикс | Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы |
| CA2598516C (en) * | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
| CA2670482C (en) * | 2006-12-05 | 2011-10-11 | Pfizer Inc. | Motilide polymorphs |
| JP6051431B2 (ja) * | 2011-03-23 | 2016-12-27 | ラクオリア創薬株式会社 | 消化管運動促進剤として機能する5−ht4受容体作動物質 |
-
2015
- 2015-05-18 US US15/306,914 patent/US9833447B2/en active Active
- 2015-05-18 CA CA2948890A patent/CA2948890C/en active Active
- 2015-05-18 TW TW104115787A patent/TWI710372B/zh active
- 2015-05-18 BR BR112016024830A patent/BR112016024830A2/pt not_active IP Right Cessation
- 2015-05-18 JP JP2016565362A patent/JP6754033B2/ja active Active
- 2015-05-18 CN CN201580024045.5A patent/CN106456620A/zh active Pending
- 2015-05-18 EP EP15793503.2A patent/EP3142666B1/de active Active
- 2015-05-18 WO PCT/JP2015/002478 patent/WO2015174098A1/en not_active Ceased
- 2015-05-18 DK DK15793503.2T patent/DK3142666T3/da active
- 2015-05-18 KR KR1020167030386A patent/KR102526521B1/ko active Active
- 2015-05-18 CN CN202111508520.XA patent/CN114344300A/zh active Pending
- 2015-05-18 RU RU2016149357A patent/RU2708686C2/ru active
- 2015-05-18 TW TW109109384A patent/TW202026002A/zh unknown
- 2015-05-18 ES ES15793503T patent/ES2812100T3/es active Active
- 2015-05-18 MX MX2016014949A patent/MX373078B/es active IP Right Grant
-
2020
- 2020-03-10 JP JP2020041183A patent/JP2020109105A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170004978A (ko) | 2017-01-11 |
| EP3142666A1 (de) | 2017-03-22 |
| MX2016014949A (es) | 2017-03-31 |
| JP6754033B2 (ja) | 2020-09-09 |
| US9833447B2 (en) | 2017-12-05 |
| TW202026002A (zh) | 2020-07-16 |
| BR112016024830A2 (pt) | 2017-08-15 |
| RU2016149357A3 (de) | 2019-01-14 |
| MX373078B (es) | 2020-07-03 |
| TWI710372B (zh) | 2020-11-21 |
| RU2708686C2 (ru) | 2019-12-11 |
| JP2017515813A (ja) | 2017-06-15 |
| WO2015174098A1 (en) | 2015-11-19 |
| HK1231414A1 (en) | 2017-12-22 |
| EP3142666A4 (de) | 2018-01-10 |
| US20170056387A1 (en) | 2017-03-02 |
| JP2020109105A (ja) | 2020-07-16 |
| CA2948890C (en) | 2022-05-10 |
| CA2948890A1 (en) | 2015-11-19 |
| EP3142666B1 (de) | 2020-06-03 |
| RU2016149357A (ru) | 2018-06-20 |
| CN114344300A (zh) | 2022-04-15 |
| ES2812100T3 (es) | 2021-03-16 |
| CN106456620A (zh) | 2017-02-22 |
| TW201625248A (zh) | 2016-07-16 |
| KR102526521B1 (ko) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251524A0 (en) | T cell receptors | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| IL252258A0 (en) | Anti-mutated kras t cell receptors | |
| CL2016002196A1 (es) | Receptor antigénico quimérico | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| HRP20181499T1 (hr) | Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora | |
| DK3140653T3 (da) | Direkte immunhistokemianalyse | |
| FI3198035T3 (fi) | Menetelmiä lääkevasteen ennustamiseksi | |
| DK3143037T3 (da) | Alpha4beta7-integrin-thioether-peptidantagonister | |
| FR3028873B1 (fr) | Installation de fractionnement | |
| IL276400A (en) | Dopamine D3 receptor antagonist compounds | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3386500T3 (da) | Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer | |
| EP3286210C0 (de) | T-zellen-rezeptor | |
| LT3233813T (lt) | Į oksatiaziną panašių junginių gavimo būdai | |
| DK3180329T3 (da) | Triazoler som nr2b receptorinhibitorer | |
| IL253848A0 (en) | Amine compounds as 5-hydroxytryptamine 4 receptor agonists | |
| DK3339706T3 (da) | Koblingsanordning til skruekobling | |
| DK3259232T3 (da) | Fremgangsmåde til aerogeler | |
| EP3394078A4 (de) | Inhibitoren des glucocorticoidrezeptors | |
| DK3183242T3 (da) | Substituerede bicykliske forbindelser | |
| EP3394079A4 (de) | Inhibitoren der glucocorticoidrezeptors | |
| DK3152383T3 (da) | Barriere | |
| BR112016027096A2 (pt) | compostos de receptores-alvo de serotonina e métodos | |
| DK3310756T3 (da) | Thromboxanreceptorantagonister |